VACCITECH PLC (VACC) Stock Price, Forecast & Analysis
USA - NASDAQ:VACC - US91864C1071 - ADR
VACC Key Statistics, Chart & Performance
The current stock price of VACC is 5 USD. In the past month the price increased by 47.06%. In the past year, price increased by 116.45%.
VACC Latest News, Press Relases and Analysis
VACC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About VACC
Company Profile
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
Company Info
VACCITECH PLC
Unit 6-10, Zeus Building, Rutherford Avenue, Harwell
Didcot OXFORDSHIRE OX4 4GE GB
CEO: William Enright
Employees: 107
Phone: 4401865818808.0
VACCITECH PLC / VACC FAQ
What does VACC do?
Vaccitech Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. The company is headquartered in Didcot, Oxfordshire and currently employs 107 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmunity. The company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The company has a pipeline of both clinical and preclinical-stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB); VTP-200 for the treatment of human papilloma virus infection (HPV); VTP-850 for the treatment of prostate cancer; VTP-600 for the treatment of non-small cell lung cancer (NSCLC); VTP-1000 for the treatment of celiac disease, and VTP-1100 for the treatment of HPV-associated cancers. Its prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles, and VTP-500 for the prevention of Middle East respiratory syndrome (MERS).
Can you provide the latest stock price for VACCITECH PLC?
The current stock price of VACC is 5 USD. The price increased by 11.36% in the last trading session.
Does VACC stock pay dividends?
VACC does not pay a dividend.
What is the ChartMill technical and fundamental rating of VACC stock?
VACC has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does VACCITECH PLC belong to?
VACCITECH PLC (VACC) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of VACC stock?
VACCITECH PLC (VACC) has a market capitalization of 192.73M USD. This makes VACC a Micro Cap stock.
VACC Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VACC. When comparing the yearly performance of all stocks, VACC is one of the better performing stocks in the market, outperforming 99.36% of all stocks.
VACC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VACC. VACC has a great financial health rating, but its profitability evaluates not so good.
VACC Financial Highlights
Over the last trailing twelve months VACC reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS decreased by -4723.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.32% | ||
| ROE | -25.29% | ||
| Debt/Equity | 0 |
VACC Forecast & Estimates
11 analysts have analysed VACC and the average price target is 9.5 USD. This implies a price increase of 89.97% is expected in the next year compared to the current price of 5.
For the next year, analysts expect an EPS growth of -1733.53% and a revenue growth -95.74% for VACC